- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- CODE OF CONDUCT
- Thank you
Magnus Nilsson hands over the baton to Dag Andersson as President and CEO of XVIVO Perfusion
XVIVO Perfusion AB's ("XVIVO") Board of Directors has decided to appoint Dag Andersson, 58, as President and CEO of XVIVO. Dag Andersson takes up his new position on June 1, 2020. Dag has a background in biotechnology as CEO of Diaverum AB from 2008 up until 2018 and before that worked for 15 years in leading roles in Mölnlycke Health Care. He holds an MBA from INSEAD and a BA (Hons) in Business and Commerce from the Stockholm School of Economics and is a Board member of Nolato AB, GHP AB and Terveystalo Oy.
The outgoing CEO Magnus Nilsson started XVIVO in 1998 with a focus on transplant products, on the advice and with the help of Dr. Peter Svalander, Vitrolife's visionary founder. Perfadex was acquired and a successful collaboration was started with Prof. Steen, which resulted in the product STEEN Solution™. Magnus was CEO of the combined transplantation and fertility company Vitrolife from January 2003 to October 2011. Under Magnus's leadership, the business showed rising sales and profits for 34 straight quarters. After the resignation Magnus was appointed CEO of XVIVO and the company was distributed to Vitrolife's shareholders in October 2012 and listed on First North. Since then, the company has grown from a handful of employees and a value of approximately SEK 240 million to a company on Nasdaq Stockholm Mid Cap with approximately fifty employees in seven countries, on three continents and with a market capitalization of approximately SEK 3,700 million. At the end of 2019, XVIVO had shown profitable growth during all 29 quarters as an independent company. During this time, XVIVO had its key products STEEN Solution™ and XPS™ PMA-approved in the US as the first company with products for warm perfusion of organs.
“The last 22 years have been fantastic fun and highly successful, and this would not have been possible without equally fantastic, enthusiastic and talented employees," says Magnus Nilsson, CEO of XVIVO Perfusion, and continues "Dag, who I know through our Board, has a very good background to continue to develop XVIVO so that it becomes a leader in the entire field of organ transplantation".
“Magnus, who will reach the age of 65 in April 2021, has done a fantastic job of building up XVIVO into a world-leading company in the field of solutions and systems for lung transplants during his nine years as CEO. I am therefore very pleased that, as part of the succession, he is staying on in a position of Senior Advisor to continue to drive a number of key areas of development. At the same time, Dag Andersson is the best conceivable candidate to take over as CEO. He has solid international experience combined with a medical technology background," says Gösta Johannesson, XVIVO´s Chairman of the Board.
It will be extremely exciting to take over the baton from Magnus and continue to build and develop XVIVO within the field of transplantation. During my time at Diaverum, I came into daily contact with patients whose greatest wish was to have a new organ transplanted. Therefore, I look forward to working on strengthening XVIVO's position in terms of both geographic presence and offering," says Dag Andersson, incoming CEO of XVIVO on June 1, 2020.
April 28, 2020
XVIVO Perfusion AB (publ)
Gösta Johannesson, Chairman of the Board
For further information please contact:
Gösta Johannesson, Chairman of the Board, +46 70 360 6210, email@example.com
Magnus Nilsson, CEO, +46 31-788 21 50, firstname.lastname@example.org
Dag Andersson, CEO as of June 1, 2020, +46-766-433031, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 6.30 pm CET on April 28, 2020.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.